Format
Sort by
Items per page

Send to

Choose Destination

Best matches for PEGFILGRASTIM/PD:

Search results

Items: 1 to 20 of 619

1.

Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.

An G.

J Clin Pharmacol. 2019 Dec 2. doi: 10.1002/jcph.1545. [Epub ahead of print] Review.

PMID:
31793004
3.

Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report.

Takuwa H, Tsuji W, Goto T, Otsuji T, Yotsumoto F.

Mol Clin Oncol. 2019 Oct;11(4):371-375. doi: 10.3892/mco.2019.1907. Epub 2019 Aug 7.

4.

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.

Wessels H, Lehnick D, Höfler J, Jankowsky R, Chamberlain P, Roth K.

Pharmacol Res Perspect. 2019 Aug 13;7(5):e00507. doi: 10.1002/prp2.507. eCollection 2019 Oct.

5.

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.

Roth K, Lehnick D, Wessels H, Höfler J, Gastl B, Jankowsky R.

Pharmacol Res Perspect. 2019 Aug 13;7(5):e00503. doi: 10.1002/prp2.503. eCollection 2019 Oct.

6.

Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.

Nishimura M, Onoe T, Sakai H, Arase M, Watanabe S, Soyama M, Hashimoto K, Miki M, Tane K, Hirokaga K, Takao S, Matsumoto K.

Anticancer Res. 2019 Aug;39(8):4379-4383. doi: 10.21873/anticanres.13607.

PMID:
31366533
7.

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies.

Brekkan A, Lopez-Lazaro L, Plan EL, Nyberg J, Kankanwadi S, Karlsson MO.

AAPS J. 2019 Jul 8;21(5):85. doi: 10.1208/s12248-019-0349-3.

8.

Pegfilgrastim and linagliptin potentiate chemoattraction of Ccr2 and Cd44 stem cells accompanied by alterations of cardiac Hgf, Igf-1 and Mcp-1 in daunorubicin cardiomyopathy.

Srankova J, Veteskova J, Marusakova M, Pivackova L, Doka G, Krenek P, Klimas J.

J Pharm Pharmacol. 2019 Sep;71(9):1440-1450. doi: 10.1111/jphp.13133. Epub 2019 Jul 3.

PMID:
31270818
9.

Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates.

Wong K, Chang PY, Fielden M, Downey AM, Bunin D, Bakke J, Gahagen J, Iyer L, Doshi S, Wierzbicki W, Authier S.

Int J Radiat Biol. 2019 Jun 21:1-12. doi: 10.1080/09553002.2019.1625488. [Epub ahead of print]

PMID:
31216213
10.
11.

Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.

Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE, Gwak HS.

Asia Pac J Clin Oncol. 2019 Aug;15(4):231-237. doi: 10.1111/ajco.13152. Epub 2019 Apr 17.

PMID:
30997742
12.

[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].

Kataoka T, Sakurashita H, Taogoshi T, Nishigakiuchi R, Murase T, Izumitani S, Saeki Y, Matsuo H.

Yakugaku Zasshi. 2019;139(4):629-633. doi: 10.1248/yakushi.18-00101. Japanese.

13.

[Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim].

Kageyama A, Nakazawa Y, Ando N, Harada D, Kitamura M, Kawakubo T, Asano K.

Gan To Kagaku Ryoho. 2019 Feb;46(2):279-281. Japanese.

PMID:
30914534
14.

LA-EP2006: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. Review.

PMID:
30887256
15.

Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim.

Shekhawat R, Shah CK, Patel A, Srinivasan S, Kapoor P, Patel S, Kumar S, Sonar S, More N, Joshi M, Patel J, Vachhani M, Kodaganti BP, Choavatiya U, Pushpaja A, Argade S, Nuwal N, Kumar M, Khambhampaty S.

PLoS One. 2019 Mar 13;14(3):e0212622. doi: 10.1371/journal.pone.0212622. eCollection 2019.

16.

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.

Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A.

Future Oncol. 2019 Apr;15(12):1313-1322. doi: 10.2217/fon-2018-0878. Epub 2019 Mar 5.

17.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

18.

Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.

Duggan C, Murphy L, Costello V, Leary EO, Yousif AD, Blazkova S, Dowling M.

Br J Nurs. 2019 Feb 28;28(4):S4-S11. doi: 10.12968/bjon.2019.28.4.S4.

PMID:
30811242
19.

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, Laurent G, Despas F.

Ann Hematol. 2019 Apr;98(4):931-939. doi: 10.1007/s00277-019-03631-z. Epub 2019 Feb 18.

PMID:
30778715
20.

Supplemental Content

Loading ...
Support Center